| 28.12 -0.2 (-0.71%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.01  |
1-year : | 39.72 |
| Resists | First : | 29.12 |
Second : | 34.01 |
| Pivot price | 26.27 |
|||
| Supports | First : | 24.11 |
Second : | 21.02 |
| MAs | MA(5) : | 27.69 |
MA(20) : | 25.32 |
| MA(100) : | 23.2  |
MA(250) : | 26.53 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 87.7 |
D(3) : | 88.6 |
| RSI | RSI(14): 66.5 |
|||
| 52-week | High : | 53.77 | Low : | 11.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AKRO ] has closed below upper band by 25.2%. Bollinger Bands are 29.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.16 - 29.31 | 29.31 - 29.43 |
| Low: | 27.76 - 27.91 | 27.91 - 28.03 |
| Close: | 27.9 - 28.14 | 28.14 - 28.33 |
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Fri, 26 Jul 2024
Ameritas Investment Partners Inc. Grows Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Fri, 26 Jul 2024
Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 139,083 Shares - Defense World
Fri, 26 Jul 2024
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by ProShare Advisors LLC - Defense World
Thu, 25 Jul 2024
Akero Therapeutics CFO sells shares worth over $4.3 million - Investing.com
Wed, 24 Jul 2024
Seven Eight Capital LP Sells 22,080 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Thu, 18 Jul 2024
Akero Therapeutics CFO sells over $976k in company stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 108.5 (%) |
| Shares Short | 6,470 (K) |
| Shares Short P.Month | 7,460 (K) |
| EPS | -3.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.3 % |
| Return on Equity (ttm) | -31.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -156 (M) |
| Levered Free Cash Flow | -95 (M) |
| PE Ratio | -8.68 |
| PEG Ratio | 0.3 |
| Price to Book value | 2.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|